ArticleACS biomaterials science & engineering2023
An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations in
Article in ACS biomaterials science & engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Engineered bacterial therapeutics from synthetic biology to clinical translation: A multi-database scientometric analysis, 2000-2026.Human vaccines & immunotherapeutics · 2026Review
- Review
- Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunotherapy development.Cancer cell international · 2026Review
- Genome-Wide Aggregated Trans-Effects Analysis Implicates Deficient Type III Interferon Signaling as a Key Cause of Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- Engineered Probiotic-Based Biomaterials for Inflammatory Bowel Disease Treatment.Theranostics · 2025Review
- Next-Generation Probiotics and Chronic Diseases: A Review of Current Research and Future Directions.Journal of agricultural and food chemistry · 2024Review
- Genetically engineered bacteria as inflammatory bowel disease therapeutics.Engineering microbiology · 2024Review
- Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions.Microbial biotechnology · 2024Review
- Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment.Exploration (Beijing, China) · 2024Review
- Research and application of intelligent diagnosis and treatment engineering bacteria.Frontiers in bioengineering and biotechnology · 2024Review
- Engineering bacterial theranostics: from logic gates toFrontiers in bioengineering and biotechnology · 2024Review
- Lipid-Encapsulated Engineered Bacterial Living Materials Inhibit Cyclooxygenase II to Enhance Doxorubicin Toxicity.Biodesign research · 2024Article
- Mechanistic insights into the role of probiotics in modulating immune cells in ulcerative colitis.Immunity, inflammation and disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The etiology of inflammatory bowel diseases (IBDs) frequently results in the uncontrolled inflammation of intestinal epithelial linings and the local environment. Here, we hypothesized that interferon-driven immunomodulation could promote anti-inflammatory effects. To test this hypothesis, we engineered probiotic
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.